ACR Meeting Abstracts

ACR Meeting Abstracts

  • Meetings
    • ACR Convergence 2024
    • ACR Convergence 2023
    • 2023 ACR/ARP PRSYM
    • ACR Convergence 2022
    • ACR Convergence 2021
    • ACR Convergence 2020
    • 2020 ACR/ARP PRSYM
    • 2019 ACR/ARP Annual Meeting
    • 2018-2009 Meetings
    • Download Abstracts
  • Keyword Index
  • Advanced Search
  • Your Favorites
    • Favorites
    • Login
    • View and print all favorites
    • Clear all your favorites
  • ACR Meetings

Abstracts tagged "clinical trial"

  • Abstract Number: 1742 • ACR Convergence 2021

    Efficacy of Anifrolumab in Serological Subgroups of Patients with SLE Participating in 2 Phase 3 Trials

    Ian N. Bruce1, Ronald Van Vollenhoven2, Yoshiya Tanaka3, Eric Morand4, Richard Furie5, Konstantina Psachoulia6, Emmanuelle Maho7, Catharina Lindholm8, Christi Kleoudis9 and Raj Tummala6, 1University of Manchester and NIHR Manchester Biomedical Research Centre, Manchester University Hospitals NHS Foundation Trust, Manchester Academic Health Science Centre, Manchester, United Kingdom, 2Amsterdam Rheumatology and Immunology Center, Amsterdam, Netherlands, 3University of Occupational and Environmental Health, Kitakyushu, Japan, 4Monash University, Melbourne, Australia, 5Zucker School of Medicine at Hofstra/Northwell Health, Great Neck, NY, 6BioPharmaceuticals R&D, AstraZeneca, Gaithersburg, MD, 7BioPharmaceuticals R&D, AstraZeneca, Cambridge, United Kingdom, 8BioPharmaceuticals R&D, AstraZeneca, Gothenburg, Sweden, 9BioPharmaceuticals R&D, AstraZeneca, Durham, NC

    Background/Purpose: In the TULIP-2 and TULIP-1 trials of patients with SLE, the type I IFN receptor mAb anifrolumab resulted in higher BILAG–based Composite Lupus Assessment…
  • Abstract Number: 1804 • ACR Convergence 2021

    Targeted Safety Analyses of Guselkumab (TREMFYA®): Long-term Results from Randomized Clinical Trials in Patients with Active Psoriatic Arthritis and Moderate to Severe Psoriasis

    Philip Mease1, Peter Foley2, Kristian Reich3, Soumya Chakravarty4, May Shawi5, Ya-Wen Yang6, Megan Miller7, Alexa Kollmeier8, Xie Xu7, Jenny Yu7, Yanli Wang7, Shihong Sheng7, Yin You7 and Iain McInnes9, 1Swedish Medical Center/Providence St. Joseph Health and University of Washington, Seattle, WA, 2University of Melbourne, Carlton, Australia, 3University Medical Center Hamburg-Eppendorf, Hamburg, Germany, 4Janssen Scientific Affairs, LLC and Drexel University College of Medicine, Horsham, PA, 5Janssen Immunology Global Commercial Strategy Organization, Toronto, ON, Canada, 6Janssen Global Services, LLC, Horsham, PA, 7Janssen Research & Development, LLC, Spring House, PA, 8Janssen Research & Development, LLC, La Jolla, CA, 9University of Glasgow, School of Medicine, Glasgow, Scotland, United Kingdom

    Background/Purpose: Guselkumab (GUS), a human monoclonal antibody that specifically binds to the p19 subunit of IL-23, demonstrated efficacy and a favorable safety profile in active…
  • Abstract Number: 0449 • ACR Convergence 2021

    Identification of Serum Protein Biomarkers at Baseline to Distinguish Radiographic Progressors from Non-Progressors in Patients with Active Psoriatic Arthritis

    Orla Coleman1, Bruna Wundervald2, Ruoyi Zhou3, James Waddington3, Robert LJ Graham4, Ciaren Graham4, Geoff McMullan4, Andrew C. Parnell5, Vinod Chandran6, Philip Mease7, Gaia Gallo8, Venkatesh Krishnan8, Stephen Pennington9 and Oliver FitzGerald10, 1Atturos, Bray, Ireland, 2Atturos, Maynooth, Ireland, 3Atturos, Belfield, Ireland, 4Queen’s University Belfast, Belfast, Northern Ireland, United Kingdom, 5Maynooth University, Maynooth, Ireland, 6Schroeder Arthritis Institute, Krembil Research Institute, Toronto Western Hospital, Toronto, ON, Canada, 7Swedish Medical Center/Providence St. Joseph Health and University of Washington, Seattle, WA, 8Eli Lilly and Company, Indianapolis, IN, 9University College Dublin, Dublin, Ireland, 10Conway Institute for Biomolecular Research, University College Dublin, Dublin, Ireland

    Background/Purpose: A delay in diagnosis and management of patients with PsA leads to poor radiographic and functional outcomes [1]. The need to identify which patients…
  • Abstract Number: 0967 • ACR Convergence 2021

    Antigen-specific and Bystander Autoreactive T Cell Control in Peripheral Blood of ACPA+ Rheumatoid Arthritis Patients Administered Antigen-specific Tolerising Immunotherapy

    Pascale Wehr1, Ranjeny Thomas2, Nishta Ramnoruth3, Swati Patel3, Jamie Rossjohn4 and Hugh Reid4, 1University of Queensland Diamantina Institute, Brisbane, Australia, 2University of Queensland, Diamantina Institute, Brisbane, Australia, 3University Of Queensland, Brisbane, Australia, 4Monash University, Melbourne, Australia

    Background/Purpose: The control of autoreactive T cells in an antigen-specific manner in autoimmune diseases is a major clinical research goal. Various regulatory immune signatures have…
  • Abstract Number: 1338 • ACR Convergence 2021

    Bimekizumab in Patients with Psoriatic Arthritis: 3-Year Results for Overall and Tumor Necrosis Factor Inhibitor (TNFi)-Naïve Populations from a Phase 2b Open-Label Extension Study

    Philip Mease1, Atul Deodhar2, Joseph Merola3, Iain McInnes4, Deepak Assudani5, Rajan Bajracharya5, Jason Coarse6, Barbara Ink7 and Georg Schett8, 1Swedish Medical Center/Providence St. Joseph Health and University of Washington, Seattle, WA, 2Oregon Health & Science University, Portland, OR, 3Brigham and Women's Hospital, Harvard Medical School, Boston, MA, 4University of Glasgow, School of Medicine, Glasgow, Scotland, United Kingdom, 5UCB Pharma, Slough, United Kingdom, 6UCB Pharma, Raleigh, NC, 7UCB Celltech, Slough, UK, Slough, United Kingdom, 8Universitätsklinikum Erlangen, Department of Internal Medicine 3 – Rheumatology and Immunology, Erlangen, Germany, Erlangen, Germany

    Background/Purpose: Bimekizumab (BKZ) is a monoclonal IgG1 antibody that selectively inhibits interleukin (IL)-17F and IL-­17A, and has demonstrated clinical improvements in joint and skin outcomes…
  • Abstract Number: 1687 • ACR Convergence 2021

    Integrated Laboratory Abnormality Profiles of Upadacitinib with up to 4.5 Years of Exposure in Patients with Rheumatoid Arthritis Treated in a Phase 3 Clinical Trial

    Christina Charles-Schoeman1, Jon Giles2, Nancy Lane3, Ernest Choy4, Dan Furst5, Jiri Vencovsky6, Anthony Wilson7, Gerd Burmester8, Tim Shaw9, Yanna Song10, Heidi Camp10, Nasser Khan10, Jillian Yee10, Samuel Anyanwu10 and Iain McInnes11, 1Department of Medicine, University of California, Los Angeles, Los Angeles, CA, 2Columbia University Irving Medical Center, Division of Rheumatology, New York, NY, 3University of California Davis, Hillsborough, CA, 4CREATE Centre, Cardiff University, Cardiff, Wales, United Kingdom, 5University of California Los Angeles, Los Angeles, CA, 6Institute of Rheumatology, Prague, Czech Republic, 7Center for Arthritis Research, Conway Institute, University College Dublin, Dublin, Ireland, 8Charité University Medicine Berlin, Berlin, Germany, 9AbbVie Inc., North Chicago, 10AbbVie Inc., North Chicago, IL, 11University of Glasgow, School of Medicine, Glasgow, Scotland, United Kingdom

    Background/Purpose: Upadacitinib (UPA) is an oral Janus kinase inhibitor approved for the treatment of rheumatoid arthritis (RA). The safety and efficacy of UPA has been…
  • Abstract Number: 1746 • ACR Convergence 2021

    Baricitinib Decreases Anti-dsDNA and IgG Antibodies in Adults with Systemic Lupus Erythematosus from a Phase 2 Double-Blind, Randomized, Placebo-Controlled Trial

    Thomas Dörner1, Ronald Van Vollenhaven2, Andrea Doria3, Bochao Jia4, Damiano Fantini4, Jorge Ross Terres4, Maria Silk5, Stephanie de Bono4, Peter Fischer6 and Daniel Wallace7, 1Charite Universitätsmedizin Berlin and Deutsches Rheumaforschungszentrum (DRFZ), Berlin, Germany, 2University Medical Center, Amsterdam, Netherlands, 3University of Padova, Padova, Italy, 4Eli Lilly and Company, Indianapolis, IN, 5Eli Lilly and Company, Carmel, IN, 6Eli Lilly and Company, North Easton, MA, 7Cedars-Sinai, Los Angeles, CA

    Background/Purpose: Baricitinib (BARI), an oral, selective Janus kinase (JAK)1 and JAK2 inhibitor, improved disease activity in adults with systemic lupus erythematosus (SLE) receiving standard background…
  • Abstract Number: 1805 • ACR Convergence 2021

    Low Rates of Radiographic Progression with 2 Years of Guselkumab (TREMFYA®), a Selective Inhibitor of the Interleukin-23p19 Subunit: Results from a Phase 3, Randomized, Double-blind, Placebo-controlled Study of Biologic-naïve Patients with Active Psoriatic Arthritis

    Philip Mease1, Alice Gottlieb2, Iain McInnes3, Proton Rahman4, Alexa Kollmeier5, Xie Xu6, Yusang Jiang6, Shihong Sheng6, May Shawi7, Soumya Chakravarty8, Frederic Lavie9 and Désirée van der Heijde10, 1Swedish Medical Center/Providence St. Joseph Health and University of Washington, Seattle, WA, 2Icahn School of Medicine at Mount Sinai, New York, NY, 3University of Glasgow, School of Medicine, Glasgow, Scotland, United Kingdom, 4Department of Medicine, Eastern Health and Memorial University of Newfoundland, St John's, NL, Canada, 5Janssen Research & Development, LLC, La Jolla, CA, 6Janssen Research & Development, LLC, Spring House, PA, 7Janssen Immunology Global Commercial Strategy Organization, Toronto, ON, Canada, 8Janssen Scientific Affairs, LLC and Drexel University College of Medicine, Horsham, PA, 9Janssen Global Services, LLC, Horsham, PA, 10Department of Rheumatology, Leiden University Medical Center, Meerssen, Netherlands

    Background/Purpose: Guselkumab (GUS), an IL-23p19-subunit inhibitor, is efficacious in treating patients (pts) with psoriasis and psoriatic arthritis (PsA). In the Phase 3, double-blind, placebo (PBO)-controlled…
  • Abstract Number: 0453 • ACR Convergence 2021

    Efficacy and Safety of Risankizumab for Active Psoriatic Arthritis: 24-Week Integrated Results from 2 Phase 3, Randomized, Double-blind Clinical Trials for CsDMARD-IR and Bio-IR Patients

    Andrew Ostor1, Kim Papp2, Mireia Moreno3, Cathy Spargo4, Lisa Barcomb5, Ahmed M. Soliman5, Wenjing Lu6, Ann Eldred5 and Lars Erik Kristensen7, 1Monash University, Cabrini Hospital, and Emertius Research, Melbourne, Australia, 2K Papp Clinical Research and Probity Medical Research, Waterloo, ON, Canada, 3Rheumatology Department, Parc Taulí Hospital Universitari, Institut d'Investigació i Innovació Parc Taulí, Universitat Autònoma de Barcelona, Barcelona, Spain, 4Vincent Pallotti Hospital, Johannesburg, South Africa, 5Abbvie Inc., North Chicago, IL, 6AbbVie Inc., North Chicago, 7The Parker Institute, Copenhagen University Hospital, Bispebjerg and Frederiksberg, Frederiksberg, Denmark

    Background/Purpose: Risankizumab (RZB) is a humanized immunoglobulin G1 monoclonal antibody that specifically inhibits interleukin 23 by binding to its p19 subunit. RZB is being investigated…
  • Abstract Number: 1169 • ACR Convergence 2021

    Patient Preferences for Outcome Measures for a Pragmatic Knee Osteoarthritis (OA) Clinical Trial: Results of a Cross-Sectional Patient Survey That Included Racial/Ethnic Minorities

    Jasvinder Singh, University of Alabama at Birmingham, Birmingham, AL

    Background/Purpose: Many effective treatments are available for knee osteoarthritis (OA), however comparative effectiveness research (CER) of various treatments to each other is limited. One of…
  • Abstract Number: 1341 • ACR Convergence 2021

    Ixekizumab Shows a Pattern of Pain Improvement in Patients with and Without Measurable Inflammation in Psoriatic Arthritis

    Kurt de Vlam1, Gaia Gallo2, Philip Mease3, Proton Rahman4, Venkatesh Krishnan2, David Sandoval2, Chen Yen Lin2, Danting Zhu2, Rebecca Bolce2 and Philip Conaghan5, 1University Hospitals Leuven, Leuven, Belgium, 2Eli Lilly and Company, Indianapolis, IN, 3Swedish Medical Center/Providence St. Joseph Health and University of Washington, Seattle, WA, 4Department of Medicine, Eastern Health and Memorial University of Newfoundland, St John's, NL, Canada, 5Leeds Institute of Rheumatic and Musculoskeletal Medicine, University of Leeds, Leeds, United Kingdom

    Background/Purpose: The efficacy of ixekizumab (IXE) and adalimumab (ADA) in patients with psoriatic arthritis (PsA) has been previously reported using ACR 50 and Psoriasis Area…
  • Abstract Number: 1688 • ACR Convergence 2021

    Safety Profile of Baricitinib for the Treatment of Rheumatoid Arthritis up to 9.3 Years: An Updated Integrated Safety Analysis

    Peter C Taylor1, Tsutomu Takeuchi2, Gerd Burmester3, Patrick DUREZ4, Josef Smolen5, Walter Deberdt6, Jinglin Zhong7, Jorge Ross Terres6, Natalia Bello6 and Kevin Winthrop8, 1University of Oxford, Oxford, United Kingdom, 2Div. Rheumatology, Keio University, Tokyo, Japan, 3Charité University Medicine Berlin, Berlin, Germany, 4Pôle de Recherche en Rhumatologie, Institut de Recherche Expérimentale et Clinique, Brussels, Belgium, 5Medical University of Vienna, Vienna, Austria, 6Eli Lilly and Company, Indianapolis, IN, 7IQVIA, Morrisville, NC, 8Oregon Health & Science University, Portland, OR

    Background/Purpose: Baricitinib (bari) is an oral selective Janus kinase (JAK)1/JAK 2 inhibitor approved for the treatment of adult patients with moderately to severely active rheumatoid…
  • Abstract Number: 1747 • ACR Convergence 2021

    BIIB059 Demonstrates Improvement in Joint Manifestations in Participants with Systemic Lupus Erythematosus in Part a of a Phase 2, Randomized, Double-Blind, Placebo-Controlled Study

    Ronald van Vollenhoven1, Richard Furie2, Kenneth Kalunian3, Maria Dall'Era4, Victoria Werth5, Xiaobi Huang6, Hua Carroll6, Cristina Musselli6, Catherine Barbey7 and Nathalie Franchimont6, 1Department of Rheumatology and Clinical Immunology, Amsterdam University Medical Center, Amsterdam Rheumatology Center, Amsterdam, Netherlands, 2Zucker School of Medicine at Hofstra/Northwell, Great Neck, NY, 3UC San Diego, La Jolla, CA, 4University of California San Francisco, Corte Madera, CA, 5Philadelphia VAMC, Philadelphia, PA, USA and Department of Dermatology, Perelman School of Medicine at the University of Pennsylvania, Philadelphia, PA, 6Biogen, Cambridge, MA, 7Biogen, Baar, Switzerland

    Background/Purpose: Joint involvement, a frequent manifestation of SLE, can be assessed using global lupus disease activity indices (SLEDAI-2K, BILAG-2004) and/or by assessing joint tenderness and…
  • Abstract Number: 1806 • ACR Convergence 2021

    Designing a Phase 3b, Multicenter, Randomized, Double-blind, Placebo-controlled Study to Investigate the Effect of Guselkumab (TREMFYA®/sup>) Dosing Interval in Psoriatic Arthritis Patients with Inadequate Response to Tumor Necrosis Factor Inhibition

    Alexis Ogdie-Beatty1, Joseph Merola2, Philip Mease3, Christopher Ritchlin4, Jose Scher5, Daphne Chan6, Soumya Chakravarty7, Wayne Langholff8, Olivia Choi9, Yevgeniy Krol9, Katelyn Rowland9 and Alice Gottlieb10, 1University of Pennsylvania, Philadelphia, PA, 2Harvard Medical School, Brigham and Women’s Hospital, Boston, MA, 3Swedish Medical Center/Providence St. Joseph Health and University of Washington, Seattle, WA, 4Division of Allergy, Immunology, and Rheumatology, School of Medicine and Dentistry, University of Rochester Medical Center, Rochester, NY, 5New York University School of Medicine, New York, NY, 6Janssen Scientific Affairs, LLC, Spring House, PA, 7Janssen Scientific Affairs, LLC and Drexel University College of Medicine, Horsham, PA, 8Janssen Research & Development, LLC, Spring House, PA, 9Janssen Scientific Affairs, LLC, Horsham, PA, 10Icahn School of Medicine at Mount Sinai, New York, NY

    Background/Purpose: Tumor necrosis factor inhibitors (TNFi) are frequently chosen as the first biologic therapy for patients (pts) with PsA, though a sizeable proportion of pts…
  • Abstract Number: 0455 • ACR Convergence 2021

    Abatacept Reverses Subclinical Arthritis in Patients with High-risk to Develop Rheumatoid Arthritis -results from the Randomized, Placebo-controlled ARIAA Study in RA-at Risk Patients

    Juergen Rech1, Mikkel Ostergaard2, Koray Tascilar3, Melanie Hagen4, Larissa Valor Mendez4, Arnd Kleyer4, Gerhard Kroenke4, David Simon5, Verena Schoenau4, Axel Hueber6, Stefan Kleinert7, Xenofon Baraliakos8, Martin Fleck9, Andrea Rubbert-Roth10, Frank Behrens11, David Kofler12, Martin Feuchtenberger13, Michael Zaenker14, Reinhard Voll15, Cornelia Glaser16, Eugen Feist17, Gerd Burmester18, Kirsten Karberg19, Johannes Strunk20, Juan D Cañete21, Esperanza Naredo22, Maria Filkova23, Ladislav Senolt24 and Georg Schett25, 1Friedrich-Alexander University (FAU) Erlangen-Nuernberg and Universitaetsklinikum Erlangen, Department of Internal Medicine 3 - Rheumatology and Immunology, Germany, Erlangen, Germany, 2Copenhagen Center for Arthritis Research, Center for Rheumatology and Spine Diseases, Rigshospitalet, Glostrup, and Department of Clinical Medicine, University of Copenhagen, Glostrup, Denmark, 3Friedrich Alexander University of Erlangen Nuremberg, Universitaetsklinikum Erlangen Department of Medicine-3 Rheumatology and Immunology, Erlangen, Germany, 4Friedrich-Alexander University (FAU) Erlangen-Nuernberg and Universitaetsklinikum Erlangen, Medical Department 3, Rheumatology & Immunology, Erlangen, Germany, 5Department of Medicine 3 - Rheumatology and Immunology, Friedrich-Alexander-University Erlangen-Nrnberg, Erlangen, Germany, 6sozialstiftung-bamberg.de, Bamberg, Germany, 7Praxisgemeinschaft Rheumatologie - Nephrologie (PGRN), Erlangen, Germany, 8Rheumazentrum Ruhrgebiet, Herne, Germany, 9Asklepios Klinikum Bad Abbach Klinik und Poliklinik für Rheumatologie/ Klin. Immunologie, Bad Abbach, Germany, 10Kantonspital St Gallen, St.Gallen, Switzerland, 11Rheumatology & Fraunhofer Institute for Translational Medicine and Pharmacology ITMP, Fraunhofer Cluster Immune-Mediated Diseases (CIMD), Fraunhofer Cluster Immune-Mediated Diseases (CIMD), Frankfurt/Main, Germany, 12Division of Rheumatology and Clinical Immunology, Department I of Internal Medicine; University Hospital Cologne, Cologne, Germany, 13MED | BAYERN OST GmbH Fachbereich Rheumatologie, Burghausen, Germany, 14Immanuel Klinikum Bernau Herzzentrum Brandenburg, Bernau, Germany, 15Department of Rheumatology and Clinical Immunology, University Medical Center, Faculty of Medicine, Albert-Ludwigs-University of Freiburg, Freiburg, Germany, 16Universitätsklinikum Freiburg Klinik für Rheumatologie und Klinische Immunologie, Freiburg, Germany, 17Helios Department of Rheumatology, Vogelsang-Gommern, Germany, 18Charité University Medicine Berlin, Berlin, Germany, 19Praxis für Rheumatologie und Innere Medizin, Berlin, Germany, 20Krankenhaus Porz am Rhein GmbH Rheumaklinik, Köln (Porz), Germany, 21Rheumatology Department, Hospital Clinic, Barcelona, Spain, 22Department of Rheumatology and Joint and Bone Research Unit, Hospital Fundación Jiménez Díaz and Autónoma University, Madrid, Spain, 23Institute of Rheumatology and Connective Tissue Research Laboratory, Department of Rheumatology of First Faculty of Medicine, Charles University in Prague, Prague, Czech Republic, 24Institute of Rheumatology, Department of Rheumatology, 1st Faculty of Medicine, Charles University, Prague, Czech Republic, 25Universitätsklinikum Erlangen, Department of Internal Medicine 3 – Rheumatology and Immunology, Erlangen, Germany, Erlangen, Germany

    Background/Purpose: Rheumatoid arthritis (RA) has a preclinical phase that is characterized by the presence of antibodies against citrullinated proteins (ACPA), subclinical arthritis and pain. ACPA…
  • « Previous Page
  • 1
  • …
  • 31
  • 32
  • 33
  • 34
  • 35
  • …
  • 44
  • Next Page »
Advanced Search

Your Favorites

You can save and print a list of your favorite abstracts during your browser session by clicking the “Favorite” button at the bottom of any abstract. View your favorites »

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].

ACR Abstract Embargo Policy

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. Academic institutions, private organizations and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part a scientific presentation or presentation of additional new information that will be available at the time of the meeting) is under embargo until Saturday, November 11, 2023.

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying financial and other sponsors about this policy. If you have questions about the abstract embargo policy, please contact the public relations department at [email protected].

Copyright Policy

View ACR Policies.

Wiley

  • Online Journal
  • Privacy Policy
  • Permissions Policies
  • Cookie Preferences

© Copyright 2025 American College of Rheumatology